scholarly journals Concentration‐QT modeling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations

2021 ◽  
Author(s):  
Veronika Voronova ◽  
Marie Cullberg ◽  
Philip Delff ◽  
Joanna Parkinson ◽  
Corina Dota ◽  
...  
Keyword(s):  
Qt Interval ◽  
Interval Prolongation ◽  
Qt Interval Prolongation ◽  
Clinically Significant

Prevalence, Management, and Clinical Consequences of QT Interval Prolongation During Treatment With Arsenic Trioxide

2014 ◽  
Vol 32 (33) ◽  
pp. 3723-3728 ◽  
Author(s):  
Gail J. Roboz ◽  
Ellen K. Ritchie ◽  
Rebecca F. Carlin ◽  
Michael Samuel ◽  
Leanne Gale ◽  
...  
Keyword(s):  
Arsenic Trioxide ◽  
Qt Interval ◽  
Interval Prolongation ◽  
Cardiac Events ◽  
Electrocardiographic Monitoring ◽  
Qt Interval Prolongation ◽  
Qt Intervals ◽  
Clinical Consequences ◽  
Study Population ◽  
Clinically Significant

Purpose Arsenic trioxide (ATO) is a highly effective agent for the treatment of acute promyelocytic leukemia (APL). QT interval prolongation is common with ATO and can pose a barrier to effective administration. The objective of this study was to characterize the prevalence, management, and clinical consequences of QT prolongation in a large cohort of patients treated with ATO. Patients and Methods We analyzed 3,011 electrocardiograms from 113 patients with non-APL acute myeloid leukemia and myelodysplastic syndrome who were treated on a previously reported clinical trial. QT intervals were assessed using four different correction formulas, and data were correlated with clinical parameters and treatment with ATO. Results There were no clinically significant cardiac events in the study population. Of those receiving ATO therapy, 29 patients (26%) had rate-uncorrected QT values above 470 ms and 13 (12%) had values exceeding 500 ms. With the commonly used Bazett rate correction formula, 102 patients (90%) had QTc greater than 470 ms, including 74 (65%) above 500 ms. By using alternative rate correction formulas, only 24% to 32% of patients had rate-corrected QT intervals above 500 ms. Conclusion QT interval prolongation is common with ATO treatment, but clinically significant arrhythmias are rare and can be avoided with appropriate precautions. Use of the Bazett correction may result in unnecessary interruptions in ATO therapy, and alternative rate correction formulas should be considered for routine electrocardiographic monitoring.

scholarly journals QT Prolongation in Critically Ill Patients With SARS-CoV-2 Infection

2022 ◽  
Vol 27 ◽  
pp. 107424842110694
Author(s):  
Wasim S. El Nekidy ◽  
Khalid Almuti ◽  
Hazem ElRefaei ◽  
Bassam Atallah ◽  
Lana M. Mohammad ◽  
...  
Keyword(s):  
Risk Factors ◽  
Critically Ill ◽  
Critically Ill Patients ◽  
Qt Interval ◽  
Interval Prolongation ◽  
Qtc Prolongation ◽  
Factors Associated ◽  
Qt Interval Prolongation ◽  
History Of ◽  
Clinically Significant

Background: Several reports linked the use of repurposed drugs such as hydroxychloroquine (HCQ), azithromycin, lopinavir/ritonavir, and favipiravir with QT interval prolongation in patients with SARS-CoV2 infection. Little is known about the risk factors for QT interval prolongation in this population. We sought to describe the prevalence and identify the main risk factors associated with clinically significant corrected QT (QTc) prolongation in this population. Methods: We conducted a retrospective analysis of critically ill patients who were admitted to our intensive care unit (ICU), had at least one electrocardiogram performed during their ICU stay, and tested positive for SARs-CoV-2. Clinically significant QTc interval prolongation was defined as QTc >500 milliseconds (ms). Results: Out of the 111 critically ill patients with SARS-CoV-2 infection, QTc was significantly prolonged in 47 cases (42.3%). Patients with a clinically significant QTc prolongation had significantly higher proportions of history of cardiac diseases/surgery (22 [46.8%] vs. 10 [15.6%], P < .001), hypokalemia (10 [21.3] vs. 5 [7.8%], P = .04), and male gender (95% vs. 82.8%, P = .036) than patients with QTc ≤500 ms, respectively. A total of 46 patients (41.4%) received HCQ, 28 (25.2%) received lopinavir/ritonavir, and 5 (4.5%) received azithromycin. Multivariate logistic regression analysis showed that a history of cardiac disease was the only independent factor associated with clinically significant QTc prolongation ( P = .004 for the likelihood-ratio test). Conclusion: The prevalence of clinically significant QTc prolongation in critically ill patients with SARS-CoV-2 infection was high and independent of drugs used. Larger prospective observational studies are warranted to elucidate independent risk factors associated with clinically significant QTc prolongation in this study population.

N C I D E N C E O F H I G H G R A D E Q T C F P R O L O N G A T I O N A N D I T S M A N A G E M E N T A M O N G P A T I E N T S U N D E R G O I N G T R E A T M E N T F O R D R U G R E S I S T A N T T U B E R C U L O S I S ( D R - T B ) : C A S E S E R I E S .

2021 ◽  
Vol 15 (2s) ◽  
pp. 38-41
Author(s):  
Meseret Asfaw ◽  
Davd Lee Holtzman ◽  
Gene F. Kwan ◽  
lawrence T. Oyewusi ◽  
carole D. Mitnick ◽  
...  
Keyword(s):  
Qt Interval ◽  
Case Series ◽  
New Drugs ◽  
World Health ◽  
High Grade ◽  
Interval Prolongation ◽  
Qt Interval Prolongation ◽  
Clinically Significant ◽  
Health Organization ◽  
Almost All

Background: The World Health Organization (WHO) has approved the use of two new drugs, namely Bedaquiline (Bdq) and Delamanid (Dlm), for treatment of Drug Resistant Tuberculosis (DR-TB). One of the concerns raised with the use of these drugs was QT-interval prolongation. This condition could be serious and life threatening. Hence, knowing the magnitude and its management is very important. This case series identifies the incidence and discusses the management of clinically significant QT-interval prolongation amongst a cohort of patients who have been on these medicines. Materials and Methods: Patients with reports of high grade QT-Interval prolongation (i.e. Grade-3 and Grade-4) were identified from the cohort of 265 patients enrolled on bedaquiline and/or delamanid and discussion is made on the pattern, severity and management of each cases identified. Results: Only 4 (1.5%) out of all 265 patients enrolled on Bedaquiline and/or Delamanid have developed high grade QT-Interval prolongation. And all are managed without permanent discontinuation of both drugs. Conclusion: The Incidence of clinically significant QTcF-interval prolongation among DR-TB patients taking bedaquiline and /or delamanid in Lesotho is low. And almost all cases can be managed with more frequent Electrocardiogram (ECG) monitoring and management of other possible causes of QT-interval prolongation without the need to stop one or both drugs permanently.

scholarly journals QT interval prolongation in asymptomatic anti-SSA/Ro–positive infants without congenital heart block

2000 ◽  
Vol 43 (5) ◽  
pp. 1049 ◽  
Author(s):  
Rolando Cimaz ◽  
Marco Stramba-Badiale ◽  
Antonio Brucato ◽  
Luca Catelli ◽  
Paola Panzeri ◽  
...  
Keyword(s):  
Qt Interval ◽  
Heart Block ◽  
Congenital Heart ◽  
Congenital Heart Block ◽  
Interval Prolongation ◽  
Qt Interval Prolongation

scholarly journals Voriconazole-Induced QT Interval Prolongation and Ventricular Tachycardia: A Non--Concentration-Dependent Adverse Effect

2004 ◽  
Vol 39 (6) ◽  
pp. e49-e52 ◽  
Author(s):  
Y. Alkan ◽  
W. E. Haefeli ◽  
J. Burhenne ◽  
J. Stein ◽  
I. Yaniv ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Ventricular Tachycardia ◽  
Qt Interval ◽  
Interval Prolongation ◽  
Qt Interval Prolongation
Sign in / Sign up

Export Citation Format

Share Document